Alliance for Clinical Trials in Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).
Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.
Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.
Top-decile sponsor footprint
Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
446 total, page 3 of 9
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT01486602
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
NCT01439711
Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
NCT01517971
Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202
NCT01503619
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
NCT01439945
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01190449
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
NCT01333033
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
NCT01376349
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
NCT01372774
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer
NCT01327794
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
NCT01336894
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
NCT01198145
Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia
NCT01284010
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
NCT01238172
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
NCT01156142
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
NCT01118013
Vitamin D and Breast Cancer Biomarkers in Female Patients
NCT01224678
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
NCT01118026
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
NCT01105312
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
NCT01167725
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT01099449
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
NCT01150045
Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
NCT01091454
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01132807
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
NCT01086605
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
NCT01085630
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Home-Based Programs for Improving Sleep in Cancer Survivors
NCT00993928
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01027000
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
NCT01057459
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT01041781
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00938470
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT01017601
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT02311907
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
NCT00956813
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01005368
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
NCT00892177
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
NCT00936702
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00826540
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
NCT00903396
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
NCT00891878
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00881361
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
NCT00601627
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00869401
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00787969
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00867321
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT00733746
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
NCT00880191
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
NCT00869206
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT00553150
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 209 |
| Phase 3 | 142 |
What is open in the Alliance for Clinical Trials in Oncology pipeline
29 recruiting of 446 indexed (7% open); 346 completed (78%).
Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide
Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 446 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- University of Virginia · 449 trials · 22% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 7% open enrollment (± trial volume)
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Insmed Incorporated · 6% recruiting · 31 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
Related
What to do with this Alliance for Clinical Trials in Oncology page
446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.
- 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets.Report a data error.